Amazon.com, 2019

John R. Wells; Benjamin  Weinstock; Gabriel  Ellsworth; Galen  Danskin

Case | HBS Case Collection | August 2015 (Revised October 2019)

Amazon.com, 2019

by John R. Wells, Benjamin Weinstock, Gabriel Ellsworth and Galen Danskin

Abstract

In January 2019, Amazon.com Inc (Amazon) became the most valuable company in the world, above Microsoft, Apple, and Alphabet (Google). Jeff Bezos, Amazon’s founder and CEO was now the world’s richest man. On January 31st, 2019, Amazon announced 2018 operating profits of $12.4 billion, up from $178 million in 2014, on sales of $232 billion, up from $89 billion four years earlier. The shareholders expressed their satisfaction, but not all were happy with Amazon’s meteoric rise. Many traditional retailers in the United States were going bankrupt, while major competitors such as Walmart and Best Buy were forced to invest aggressively in online retailing to prevent their market share from eroding. Every retail sector appeared to be under threat, fueling anxieties that Amazon and America’s other tech giants were becoming too big and powerful. In the United States, Amazon was drawing criticism from across the political spectrum, with calls for it to be broken up. Meanwhile, the European Union was also investigating its practices. Did Amazon’s success threaten its very existence?

Keywords: Strategic Analysis; retail; e-commerce; Amazon; internet; Amazon.com; AmazonFresh; Jeff Bezos; Cloud Computing; marketplaces; streaming; e-reader market; digital media; mobile app; online retail; shipping; database; Tablet; Kindle; Kindle Fire; smartphone; delivery; Market Platforms; Two-Sided Platforms; Competition; Internet; Corporate Strategy; Online Advertising; Business Growth and Maturation; Business Model; Business Organization; For-Profit Firms; Film Entertainment; Games, Gaming, and Gambling; Music Entertainment; Television Entertainment; Profit; Revenue; Global Strategy; Multinational Firms and Management; Taxation; Business History; Human Resources; Resignation and Termination; Books; Human Capital; Working Conditions; Business or Company Management; Goals and Objectives; Growth and Development Strategy; Growth Management; Management Practices and Processes; Industry Growth; Industry Structures; Media; Distribution; Distribution Channels; Order Taking and Fulfillment; Infrastructure; Logistics; Product Development; Supply Chain; Supply Chain Management; Organizational Culture; Public Ownership; Work-Life Balance; Problems and Challenges; Labor and Management Relations; Strategy; Adaptation; Business Strategy; Competitive Strategy; Diversification; Expansion; Integration; Horizontal Integration; Vertical Integration; Hardware; Information Technology; Mobile Technology; Online Technology; Technology Networks; Technology Platform; Web; Web Sites; Price; Software; Marketing; Marketing Strategy; Working Capital; Customer Focus and Relationships; Customer Value and Value Chain; Retail Industry; Advertising Industry; Distribution Industry; Electronics Industry; Entertainment and Recreation Industry; Information Technology Industry; Manufacturing Industry; Motion Pictures and Video Industry; Music Industry; Publishing Industry; Shipping Industry; Technology Industry; Video Game Industry; Web Services Industry; United States; Washington (state, US); Seattle;

Language: English

Format: Print

45 pages

Educators Purchase

Citation:

Wells, John R., Benjamin Weinstock, Gabriel Ellsworth, and Galen Danskin. "Amazon.com, 2019." Harvard Business School Case 716-402, August 2015. (Revised October 2019.)

Case | HBS Case Collection | September 2020

Minerva 2004: Discovery

John R. Wells, Benjamin Weinstock, John R. Wells and Benjamin Weinstock

After nearly five years in operation, Doctor Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), was reflecting on the company’s next steps. In a few short years, she and her small team had managed to develop a nanoparticle process for testing new drugs that was orders of magnitude faster than traditional approaches. Using this process, they had discovered the mechanism that caused 96% of all breast cancers and identified families of small molecule therapeutics that were effective in blocking this mechanism in live cells in the laboratory. Moreover, Bamdad did not think it would be long before the company could offer an early warning diagnostic for breast cancer, which would allow less invasive treatment of the condition. The company had filed several families of patent applications in support of these claims, but the challenge was funding. To date, Bamdad had relied on Federal Government grants and angel investors to fund the research, but the next steps would require much larger investment. Should Minerva seek to commercialize its drug development technology to help fund the riskier steps of drug development? Should it focus on a diagnostic which would make current treatments more effective? Should it license its small molecule therapeutics to one of the many well-funded companies seeking cures for cancer? Or should Bamdad raise capital to support tests in mice in order to reach the Federal Drug Administration IND (Investigational New Drug) application stage of drug discovery? This would allow clinical trials in humans, which would require more capital, but an IND would increase the value of Minerva’s intellectual capital substantially. What should Bamdad do?

Keywords: Entrepreneurship; Financing and Loans; Strategy; Decision Choices and Conditions; Biotechnology Industry;

Citation:

Wells, John R., and Benjamin Weinstock. "Minerva 2004: Discovery." Harvard Business School Case 721-389, September 2020. View Details

Cite View Details Educators Purchase

In 2010, amid a flurry of new discoveries, Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), raised $6.6 million to test her new cancer drugs in mice. It had been more than 6 years since she had announced that she and her small team at Minerva had identified the mechanism that caused 96% of all breast cancers and had discovered a number of small molecule drugs and antibodies to block it. Funding the next stage of development had proven very difficult, but, undeterred, Bamdad had raised enough to keep her laboratory open and continue her research work. In the process, she made the startling discovery that the “cancer” mechanism she had discovered was an integral part of the production of all human embryonic stem cells, and that cancer was a result of this mechanism going awry. As a result, Minerva developed the ability to produce high-quality stem cells, which opened up a whole range of new commercial opportunities for the company, including advanced therapeutics and processes for growing and replacing human cells of all types. However, resources were limited. Where should she focus her efforts?

In March 2020, Dr. Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Inc. (Minerva), was reviewing the first results of human clinical trials for the company’s novel CAR-T drug therapeutic, one of the first ever to target solid cancer tumors. The results looked promising.
CAR-T therapeutics were a new field attracting a lot of scientific interest. They involved genetically re-engineering a patient’s T-cells, a key element of the human immune system, to attack the cancer. The first CAR-T treatments for cancer were developed for the relatively small field of blood cancers, 7% of all cancers. For instance, early pioneer Kite Pharma Inc. (Kite) developed a treatment for a special type of lymphoma that only affected 7,500 patients a year. Still, the financial interest was huge, and Kite was acquired by Gilead Sciences Inc. in August 2017 for $11.9 billion. Similarly, Juno Therapeutics Inc. was acquired by Celgene Corporation for $9 billion in January 2018.
Minerva’s therapeutics targeted 96% of all breast cancers and 46% of prostate cancers, a market that was orders of magnitude larger. After 21 years, Bamdad believed that Minerva was on the threshold of something really big.
Should Bamdad sell the business and work within a larger organization? Or should she IPO and continue to develop the company’s long-term pipeline of therapeutics and diagnostics?

Faculty & Research

Amazon.com, 2019

Abstract

Citation:

About the Author

More from the Author

Faculty & Research

Amazon.com, 2019

Abstract

Citation:

Related Work

About the Author

More from the Author